Doubling down on its strategy, Pfizer names its head of oncology as new research chief
Pfizer, despite pressure from investors to look outside, elevates its cancer chief Chris Boshoff to lead overall R&D.
Pfizer promoted oncology chief Chris Boshoff to serve as CSO, R&D president
As for his soon-to-be former role, Boshoff will be succeeded by Dr. Roger Dansey, who will serve as the interim chief oncology officer. He will then hand off the role to Dr. Johanna Bendell, who will join the Pfizer team in 2025.
Pfizer elevates Chris Boshoff to top R&D role
"Dr Boshoff is the ideal leader to propel Pfizer's R&D engine forward and transform it into a world-leading organisation with a more focused strategy, driving the delivery of additional impactful breakthrough medicines with blockbuster potential," said chief executive Albert Bourla.
Pfizer, under pressure to change, names oncology head as new R&D chief
Chris Boshoff will replace Mikael Dolsten, who’s stepping down after 15 years leading research at the drugmaker.
Pfizer confirms Chris Boshoff as chief scientific officer
Pfizer (PFE) announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD,
Pfizer names head of oncology as new R&D chief
Pfizer (PFE) appoints Chris Boshoff as its new Chief Scientific Officer and President, R&D to replace the outgoing science chief Mikael Dolsten. Read more here.
Pfizer Announces New Chief Scientific Officer and President, Research & Development
Pfizer Inc. (NYSE: PFE) today announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, as Chief Scientific Officer and President,
Leerink views Chris Boshoff as ‘strong choice’ for Pfizer’s CSO
Leerink notes Pfizer (PFE) announced that Chris Boshoff will become the new Chief Scientific Officer, succeeding Mikael Dolsten. The firm views
Pfizer names oncology chief Chris Boshoff as new chief scientific officer
Pfizer Inc. named oncology chief Chris Boshoff as its new chief scientific officer on Wednesday, replacing Mikael Dolsten starting Jan. 1. The drug company had been searching for a new chief scientific officer since July with Dolsten leaving after 15 years at the company,
Pfizer promotes oncology chief to lead R&D as activist Starboard circles
Pfizer has promoted its oncology chief to lead all of its research and development operations, in a move that will be closely watched by the activist investor piling pressure on the struggling drugmaker.
Pfizer names oncology head Chris Boshoff as R&D chief
Pfizer said on Wednesday it has named company veteran and oncology head Chris Boshoff as its chief of research and development. The appointment comes at a time when Pfizer is facing criticism from activist investor Starboard for overspending on big acquisitions and failing to produce profitable new drugs from those deals or its internal research and development.
FierceBiotech4d
Pfizer plucks internal candidate to replace R&D head Dolsten, triggering series of leadership shakeups
Pfizer has found a successor for Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the company’s own ...
BioSpace4d
Pfizer Shakes Up C-Suite, Elevating Cancer Chief Boshoff to CSO
Chris Boshoff will take over as Pfizer’s next chief scientific officer as of January 1, replacing Mikael Dolsten who led the ...
Pfizer Taps Cancer Chief to Lead Research, Find Hit Drugs
Pfizer Inc. named oncology research head Chris Boshoff as the drug company’s chief scientific officer while it works to fend ...
Borsa Italiana2d
Pfizer names Chris Boshoff as chief scientific officer
Replaces Mikael Dolsten (Il Sole 24 Ore Radiocor) - New York, 20 Nov - The US pharmaceutical Pfizer said that it has appointing Chris Boshoff as chief scientific officer and president in charge of ...